Abstract 2336P
Background
Epithelial-mesenchymal transition (EMT) is one of the major molecular mechanisms inducing tumor invasion and metastasis. Various MicroRNAs (miRNAs) have been shown to be involved in EMT. MiR-155 is consistently up-regulated in non-small cell lung cancer and is associated with poor overall survival. Whether miR-155 regulates EMT in lung cancer cells remains unclear.
Methods
We first transfected plasmid containing miR-155 into H1299 and A549 cells and established H1299-miR-155 and A549-miR-155 cells. Western blotting was done to demonstrate E-cadherin, vimentin, and Quaking (QKI) expression in H1299-miR-155 and A549-miR-155 cells. Invasion and migration assay were performed in H1299-miR-155 and A549-miR-155 cells. We then constructed p-mcherry plasmids that contain miR-155 and a p-Luc-QKI-3’UTR reporter plasmid. Luciferase assay was done to demonstrate whether miR-155 binds to the QKI 3’UTR.
Results
Quantitative RT-PCR showed that QKI expression was downregulated in H1299-miR-155 and A549-miR-155 cells. Western Blotting showed decreased E-cadherin and increased vimentin expression in H1299 and A549 cells after miR-155 transfection. Western blotting also showed decreased QKI expression in H1299 and A549 cells after miR-155 transfection. Migration assay showed that the number of migrated cells significantly increased after miR-155 transfection in H1299 and A549 cells. Invasion assay showed that the number of invaded cells also significantly increased after miR-155 transfection in H1299 and A549 cells. We constructed p-mcherry plasmids that contain miR-155 and a p-Luc-QKI-3’UTR reporter plasmid. Luciferase assay showed that miR-155 represses the activity of p-Luc-QKI-3’UTR. We then mutated the miR-155 binding site in the QKI 3’UTR to confirm that repression of the mRNA levels is induced by the binding of miR-155 to the QKI 3’UTR.
Conclusions
MiR-155 overexpression regulates EMT through repressing QKI in lung cancer cells. Repression of QKI is induced by the binding of miR-155 to the QKI 3’UTR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16